Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05795595 · ClinicalTrials.gov registry record · Phase 1
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
A Phase 1 study of Pancreatic Adenocarcinoma and Clear Cell Renal Cell Carcinoma, sponsored by CRISPR Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 7
- Study locations
NCT05795595: Completed Phase 1 study of Pancreatic Adenocarcinoma and Clear Cell Renal Cell Carcinoma, sponsored by CRISPR Therapeutics.
NCT05795595 is a Phase 1 study of Pancreatic Adenocarcinoma and Clear Cell Renal Cell Carcinoma that has completed, run by CRISPR Therapeutics. The registered enrollment target is 19 participants, below the 99,465-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (100% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05795595, a Phase 1 study of Pancreatic Adenocarcinoma and Clear Cell Renal Cell Carcinoma, has completed, sponsored by CRISPR Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX131™ in subjects with relapsed or refractory solid tumors.
Primary Outcome
Defined as dose-limiting toxicities
Conditions Studied
Interventions
- BIOLOGICAL CTX131
Study Locations (7)
California
- Research Site 3 - Duarte
Illinois
- Research Site 7 - Chicago
Massachusetts
- Research Site 6 - Boston
Missouri
- Research Site 2 - St Louis
North Carolina
- Research Site 4 - Durham
Tennessee
- Research Site 1 - Nashville
Texas
- Research Site 5 - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2023-03-13 |
| Est. Completion | 2025-09-18 |
| Phase | Phase 1 |
What the finished NCT05795595 record still lists
NCT05795595 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 99,465-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (100% lower).
The record links to 5 conditions, with Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which CTX131 is the first listed.
NCT05795595 lists 7 locations in 7 states (California, Illinois, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT05795595 about?
NCT05795595 is a clinical study titled "A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors". This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX131™ in subjects with relapsed or refractory solid tumors.
What is the current status of trial NCT05795595?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2023-03-13. Estimated completion is 2025-09-18.
What conditions does trial NCT05795595 study?
This clinical trial studies the following conditions: Pancreatic Adenocarcinoma, Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma, Malignant Pleural Mesothelioma.
What interventions are being tested in trial NCT05795595?
The interventions under investigation include: CTX131 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05795595?
This trial is sponsored by CRISPR Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05795595 being conducted?
This trial has 7 study locations across California, Illinois, Massachusetts, Missouri, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05795595's enrollment target sits among peer trials
19 54th of 62 higher than 8 of 62 other Pancreatic Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
RECRUITING · Phase 1
-
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
RECRUITING · Phase 1
-
Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma
RECRUITING · Phase 1
-
Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI